title: Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.
abstract: Treatment of chronic lymphocytic leukemia (CLL) patients with standard dose infusion of rituximab (RTX), 375 mg/m2, induces clearance of malignant cells from peripheral blood after infusion of 30 mg of RTX. After completion of the full RTX infusion, substantial recrudescence of CLL cells occurs, and these cells have lost > 90% of CD20. To gain insight into mechanism(s) of CD20 loss, we investigated the hypothesis that thrice-weekly low-dose RTX (20 or 60 mg/m2) treatment for CLL over 4 wk would preserve CD20 and enhance leukemic cell clearance. During initial infusions in all 12 patients, the first 30 mg of RTX promoted clearance of > 75% leukemic cells. Four of six patients receiving 20 mg/m2 RTX retained > or = 50% CD20, and additional RTX infusions promoted further cell clearance. However, four of six patients receiving 60 mg/m2 had CD20 levels < 20% baseline 2 days after initial infusions, and additional RTX infusions were less effective, presumably due to epitope loss. Our results suggest that when a threshold RTX dose is exceeded, recrudesced RTX-opsonized cells are not cleared, due to saturation of the mononuclear phagocytic system, but instead are shaved of RTX-CD20 complexes by acceptor cells. Thrice-weekly low-dose RTX may promote enhanced clearance of circulating CLL cells by preserving CD20.
authors.affiliation: Hematology/Oncology Division and Hematologic Malignancy Program, University of Virginia Health System, Charlottesville, VA 22908-0733, USA.
authors.forename: Michael E
authors.initials: ME
authors.lastname: Williams
authors.forename: John J
authors.initials: JJ
authors.lastname: Densmore
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Pawluczkowycz
authors.forename: Paul V
authors.initials: PV
authors.lastname: Beum
authors.forename: Adam D
authors.initials: AD
authors.lastname: Kennedy
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Lindorfer
authors.forename: Susan H
authors.initials: SH
authors.lastname: Hamil
authors.forename: Jane C
authors.initials: JC
authors.lastname: Eggleton
authors.forename: Ronald P
authors.initials: RP
authors.lastname: Taylor
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000097:blood*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D003176:Complement C3 / Q000378:metabolism; D004306:Dose-Response Relationship, Immunologic; D004334:Drug Administration Schedule; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000276:immunology* / Q000628:therapy*; D018655:Lymphocyte Count; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D003176:Complement C3; D000069283:Rituximab